Clinical characteristics and outcomes of Richter transformation: Experience of 204 patients from a single center

Yucai Wang, Marcella A. Tschautscher, Kari G. Rabe, Timothy G. Call, Jose F. Leis, Saad S. Kenderian, Neil E. Kay, Eli Muchtar, Daniel L. Van Dyke, Amber B. Koehler, Susan M. Schwager, Susan L. Slager, Sameer A. Parikh, and Wei Ding

Disclosures: This study was supported by grants from the National Institute of Health Lymphoma SPORE CA 97274 and K23 CA160345, K12 CA090628, Richard M. Schulze Family Foundation for Awards in Cancer Research, the Fraternal Order of Eagles Cancer Research Fund, and the Predolin Foundation. S.A.P. and S.S.K. are recipients of the K12 CA090628 grant from the National Cancer Institute (Paul Calabresi Career Development Award for Clinical Oncology). W.D. reports research funding from Merck & Co., Inc and has been on advisory board for Merck, Octapharma and Alexion. S.A.P. reports research funding from Pharmacyclics, MorphoSys, Janssen, AbbVie, AstraZeneca, Genentech, GlaxoSmithKline, Celgene, and Ascentage Pharma, and has been an advisory board for Pharmacyclics, AstraZeneca, Gilead, and AbbVie. S.S.K. reports research funding from Novatis, Kite/Gilead, Tolero, Humangene, Lentigen, Actinium, MorphoSys, and has been on advisory board for Humangene. The rest of co-authors declare no competing interests. N.E.K. reports research funding from Pharmacyclics, Tolera, Acerta, and has been on advisory board for AstraZeneca, Gilead, MorphoSys, Infinity Pharm, Celgene, and Agios Pharm & Cytomx Therapeutics.

Contributions: W.D. and S.A.P. designed the study. Y.W., M.A.T. and K.G.R. collected data. K.G.R., Y.W., S.A.P. and W.D. analyzed and interpreted data. Y.W. wrote the first draft of the manuscript. All authors reviewed and revised the manuscript.